Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide Administered With a Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide Administered With a Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; EMD 640744 (Primary) ; Pembrolizumab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms SPiReL
  • Most Recent Events

    • 18 Sep 2018 Results presented in the IMV media release.
    • 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
    • 28 Mar 2018 According to an Immunovaccine media release, first patient has been treated in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top